Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: ASHS provides Gamma Knife stereotactic radiosurgery services to 21 medical centers across 18 states through its 81% owned subsidiary, GK Financing, LLC (GKF). The remaining 19% of GKF is owned by Elekta AG. Gamma Knife services accounted for 100% of revenue in 2006. The company is also developing a Proton Beam Radiation Therapy (PBRT) business via an investment in Still River Systems, Inc., and an Image Guided Radiation Therapy (IGRT) system.
Key Financial Metrics
| Metric (in thousands) | 2006 | 2005 |
|---|---|---|
| Medical Services Revenue | $20,385 | $18,231 |
| Costs of Operations | $10,365 | $9,072 |
| Gross Margin | $10,020 (49.2%) | $9,159 (50.2%) |
| Operating Income | $3,864 | $3,471 |
| Net Income | $1,656 | $1,767 |
| Diluted EPS | $0.33 | $0.35 |
| Cash and Cash Equivalents | $3,952 | $1,298 |
| Total Debt & Capital Leases | $21,082 | $25,080 |
| Working Capital | ($541) | $2,423 |
Dividends: $0.1900 per share declared in 2006 (payout ratio 58%).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11.8% to $20.4 million, driven by the full-year inclusion of three new Gamma Knife units and a 5.1% increase in average revenue per procedure.
- Net Income Decline: Despite an 11.3% increase in operating income, net income decreased 6.3% to $1.66 million. This was primarily due to a $422,000 increase in income tax expense (effective rate rose to 42% from 31% in 2005) and increased minority interest expense.
- Liquidity Shift: Working capital turned negative ($541k deficit) compared to a positive $2.4 million in 2005. This was caused by drawing $4 million on a line of credit to fund investments in PBRT equipment and deposits, which is classified as a current liability.
- Cost Increases: Costs of operations rose 14.3% due to warranty expirations on three units and increased depreciation from new units and upgrades.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to renew its $6 million line of credit in 2007. The company anticipates continued profitability but notes that future revenue depends on securing new sites and maintaining reimbursement rates.
- Strategic Investments: ASHS has committed significant capital to the PBRT business, including a $2 million equity investment in Still River and deposits for two Clinatron 250 systems (total commitment up to $6 million). These systems are not yet FDA approved and are not expected to generate revenue before 2010.
- Key Risks:
- Reimbursement Rates: Revenue is sensitive to Medicare and third-party payer rates. While outpatient rates increased 24% in 2007, future reductions could impact revenue sharing contracts.
- Debt Levels: The company carries high debt ($21.1 million) collateralized by equipment. Default could lead to asset seizure.
- Technology Obsolescence: New models (e.g., Perfexion) render older units non-upgradeable, requiring capital reinvestment.
- Customer Concentration: One customer accounted for 13% of 2006 revenue.
- Unusual Items: The adoption of SFAS 123(R) in 2006 resulted in a $39,000 stock-based compensation expense, whereas prior years utilized the intrinsic value method with no expense recognized.
Investor Verification Checklist
- Debt Covenants: Verify compliance with all debt covenants given the high leverage and recent draw on the line of credit.
- PBRT Investment Status: Monitor FDA approval progress for Still River Systems and the timeline for revenue generation from the Clinatron 250 units.
- Reimbursement Trends: Track Medicare APC rate changes and their specific impact on the five revenue-sharing contracts.
- Contract Renewals: Review the status of contracts expiring in late 2007 and early 2008 to assess renewal risks.
- Working Capital: Assess the sustainability of negative working capital and the company's ability to service the $4 million line of credit.